INVESTORS
Leading the future of self-care
Maxwellia is a fast-growing, female-founded consumer healthcare company revolutionising access to medicines. We convert prescription-only drugs into consumer friendly over-the-counter (OTC) brands, and we do it quickly and efficiently using our proven DynamicSwitch™ process. We’re empowering consumers to take control of their health while driving transformative growth in the £288bn global OTC market.
Backed by prominent investors, including Praetura Ventures, Channel 4 Ventures and the British Business Bank, along with the highly successful private investor, John Gunn, Maxwellia is uniquely positioned to lead the next wave of consumer healthcare innovation.
Always read the label
Current funding round
Our latest funding round is now closed.
We’re pleased to share that our recent funding round was oversubscribed and is now closed. Due to strong demand, we will be opening a further round in due course. To be among the first to hear when the next opportunity becomes available, we invite you to join our investor wait list by signing up below.
ABOUT YOUR EIS INVESTMENT
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment.
Your investment in Maxwellia can benefit from the Enterprise Investment Scheme (EIS). EIS offers a range of benefits to investors:
Maxwellia is a Knowledge-Intensive Company
1. Income Tax Relief
Investors can claim up to 30% relief on investments in EIS-qualifying shares, up to £1 million annually (£2 million for Knowledge-Intensive Companies). The investment must be held for at least 3 years, and investors can "carry back" the relief to the previous tax year.
2. Capital Gains Tax (CGT) Freedom
No CGT is payable on shares sold after 3 years if income tax relief was received
and not withdrawn.
3. CGT Deferral Relief
Investors can defer CGT on gains from other assets by investing in EIS shares. The deferral lasts as long as the EIS shares are held.
4. Loss Relief
If shares are sold at a loss, the loss can be offset against capital gains or income, reducing the investment risk.
5. Business Relief for Inheritance Tax (IHT)
EIS shares may qualify for 100% IHT relief after 2 years, potentially eliminating inheritance tax on the investment.